IGF-I, IGF-II STUDY IN PATIENTS WITH EARLY STAGING BREAST CANCER

Issue: 
11
Year: 
2016

U.R. Mamedov
Ph.D. (Med.), Senior Research Scientist, N.N. Blokhin Russian Cancer Research Center (Moscow)
O.I. Kostileva
Ph.D. (Med.), Senior Research Scientist, N.N. Blokhin Russian Cancer Research Center (Moscow)
E-mail: biochimia@yandex.ru
V.D. Ermilova
Ph.D. (Med.), Leading Research Scientist, N.N. Blokhin Russian Cancer Research Center (Moscow)
A.V. Maslyaev
Oncologist, N.N. Blokhin Russian Cancer Research Center (Moscow)
I.K. Vorotnikov
Dr.Sc. (Med.), Professor, N.N. Blokhin Russian Cancer Research Center (Moscow)

The investigation of serum IGF-I and IGF-II levels in 293 breast cancer patients staging T1-T2N0M0 and in 75 practically healthy women was carry out. The literature data on lower serum level of IGF-I and higher IGF-II in patients with breast cancer compared to the control group. Serum level of IGF-II showed good diagnostic capabilities in case of detection of the primary breast tumor in women under age 50 years (sensitivity 76,7%, specificity 94,1%). Comparative analysis of serum levels of IGF-I and IGF-II in patients with breast cancer and in healthy women demonstrated convincingly the relationship of these markers with specific biological characteristics of the tumor and demonstrated the prospects of using these markers to diagnose breast cancer.

Keywords: 
Key words: IGF-I
IGF-II
early breast cancer.